All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 25, 2021
Home » Blogs » BioWorld Perspectives » Sequencing & Privacy Concerns: Is the Cuckold the Elephant in the Room?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Genomics / Medicare

Sequencing & Privacy Concerns: Is the Cuckold the Elephant in the Room?

Oct. 14, 2011
By Anette Breindl
No Comments

MONTREAL ‑ At this week’s American Society for Human Genetics annual meeting, where there is a whole genome sequence there is somebody bringing up privacy concerns. Do you really want your genome data to be laid bare? Will it start in a research database, move to your doctor’s office, and soon enough be found floating around on the Internet?

Most of those privacy concerns focus on medical issues, which makes a lot of sense. Certainly, most people would not feel warm and fuzzy about having their insurance companies know that, like Craig Venter, they have a higher-than-average risk of developing Alzheimer’s disease.

Nor do people necessarily want to know these things themselves, especially when there’s nothing to be done about the disease in question. Nobelist James Watson recounted specifically refusing to have his ApoE status made public, or even to find out about it himself. He had a grandmother with late-onset Alzheimer’s disease and doesn’t really want to know what the future may or may not hold.

Watson’s ApoE status can, of course, be inferred from his variants in nearby genes.

And the question of how medically useful genomes will be if their owners refuse to find out about the medically relevant alleles is a whole other question, of course. I suppose that this one will be solved with the passage of time, as more and more risk variants are discovered and that stretch of base pairs that is now mind-numbingly boring turns out to harbor a risk variant for something nasty.

Still, one thing I haven’t heard mentioned is this: the best guess for the percentage of children born to married parents whose biological father is someone other than the husband of their mother is 8 percent to 15 percent. Precise data, for obvious enough reasons, are hard to come by. But for men whose suspicions are large enough to get paternity testing done, the number is 30 percent.

If genome or exome sequencing becomes part of routine medical care, what happens when the sequence data doesn’t align?

Watson is clearly less worried about his wife than he is about his grandmother. In his plenary talk, he expressed his frustration that his son Rufus, who has schizophrenia, refuses to be sequenced – to ease his own worries: “The moment you have a son that’s not normal, you wonder whether you could have done something different,” he told the audience. In such cases, he thinks that sequencing of parents and their children could put the parent’s mind at ease that their children’s condition is due to “a genetic injustice, not something you did . . knowing that won’t make their child healthy, but parents won’t have the double whammy of thinking they did something wrong.”

I feel for Dr. Watson; and at the same time, I think about some other family that does get sequenced, and then has its own double whammy of illness and paternity to deal with. Or of the family that refuses to get sequenced. Will such refusal, for whatever reasons, in time come to be seen as a tacit admission that there’s something to hide?

I have no answer – I doubt there is a good answer. Certainly, the answer cannot be to forgo sequencing and the medical opportunities it offers. Still, I’m glad I’m not the family doctor who, in a few years, will take those cheek swabs ‑ and then, every so often, will need to figure out what to say about the results.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing